Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland.
Policlinico G.B. Rossi, Verona, Italy.
Bone Marrow Transplant. 2020 Jan;55(1):126-136. doi: 10.1038/s41409-019-0624-z. Epub 2019 Aug 27.
Information on incidence, and factors associated with mortality is a prerequisite to improve outcome after hematopoietic stem cell transplantation (HSCT). Therefore, 55'668 deaths in 114'491 patients with HSCT (83.7% allogeneic) for leukemia were investigated in a landmark analysis for causes of death at day 30 (very early), day 100 (early), at 1 year (intermediate) and at 5 years (late). Mortality from all causes decreased from cohort 1 (1980-2001) to cohort 2 (2002-2015) in all post-transplant phases after autologous HSCT. After allogeneic HSCT, mortality from infections, GVHD, and toxicity decreased up to 1 year, increased at 5 years; deaths from relapse increased in all post-transplant phases. Infections of unknown origin were the main cause of infectious deaths. Lethal bacterial and fungal infections decreased from cohort 1 to cohort 2, not unknown or mixed infections. Infectious deaths were associated with patient-, disease-, donor type, stem cell source, center, and country- related factors. Their impact varied over the post-transplant phases. Transplant centres have successfully managed to reduce death after HSCT in the early and intermediate post-transplant phases, and have identified risk factors. Late post-transplant care could be improved by focus on groups at risk and better identification of infections of "unknown origin".
有关发病率和与死亡率相关的因素是改善造血干细胞移植(HSCT)后结局的前提。因此,在一项里程碑式分析中,对 114491 例接受 HSCT(83.7%为异基因)的白血病患者在第 30 天(极早期)、第 100 天(早期)、第 1 年(中期)和第 5 年(晚期)的死亡原因进行了调查。在自体 HSCT 后的所有移植后阶段,自队列 1(1980-2001 年)到队列 2(2002-2015 年),所有原因导致的死亡率均下降。异基因 HSCT 后,感染、GVHD 和毒性导致的死亡率在 1 年内下降,5 年内上升;移植后各阶段的复发死亡率均增加。不明原因的感染是感染性死亡的主要原因。从队列 1 到队列 2,致死性细菌和真菌感染减少,但不明原因或混合感染没有减少。感染性死亡与患者、疾病、供者类型、干细胞来源、中心和国家相关因素有关。它们的影响在移植后各阶段有所不同。移植中心成功地降低了 HSCT 后早期和中期的死亡率,并确定了风险因素。通过关注高危人群和更好地识别“不明原因”感染,可以改善晚期移植后的护理。